Trial Profile
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Meningococcal vaccine group B; Pneumococcal vaccine conjugate; RIX 4414
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Registrational; Therapeutic Use
- Acronyms MET52
- Sponsors Sanofi; Sanofi Pasteur
- 08 Jun 2023 Status changed from active, no longer recruiting to completed.
- 14 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2022 Planned End Date changed from 19 Nov 2022 to 20 Jan 2023.